高级检索
当前位置: 首页 > 详情页

MiR-205 is implicated in migration and invasion of non-small cell lung cancer H460 cells through targeting vimentin

| 认领 | 导出 |

文献详情

资源类型:
机构: [1]Huazhong Univ Sci & Technol, Tongji Med Coll, Union Hosp, Canc Ctr, 156 Wujiadun, Wuhan 430023, Hubei, Peoples R China; [2]Sun Yat Sen Univ, Canc Ctr, 2State Key Lab Oncol South China, Collaborat Innovat Ctr Canc Med, Guangzhou, Guangdong, Peoples R China; [3]Sun Yat Sen Univ, Canc Ctr, Dept Mol Diagnost, Guangzhou, Guangdong, Peoples R China
出处:
ISSN:

关键词: miR-205 migration invasion NSCLC Vimentin

摘要:
Lung cancer is one of the most common malignancies and the leading cause of cancer related death in the world. Despite of advances in several treatment strategies, the prognosis of advanced non-small cell lung cancer (NSCLC) is unfavorable. MicroRNAs have been implicated in cancer development and progression. In this study, we investigated the role of miR-205 in the migration and invasion of NSCLC. To generate tumor-repopulating cells (TRCs), we cultured NSCLC cell line H460 in three-dimension (3D) soft fibrin gels. H460-TRCs cultured in 3D soft fibrin gels exhibited increased migration and invasion ability, along with significantly up-regulated expression of EMT and stemness associated genes and protein. Moreover, further investigation on the microRNAs profile of H460-TRCs showed that the expression of miR-205 was decreased in H460-TRCs. Down regulating the expression of miR-205 with inhibitor in H460 led to enhanced migration and invasion ability and increased Vimentin protein expression. We focused on miR-205 and identified its target according to bioinformatics analysis. Further data showed that silencing Vimentin resulted in decreased colony-formation, migration and invasion ability. These results suggested that miR-205 may play a critical role through vimentin in NSCLC migration and invasion.

基金:
语种:
WOS:
中科院(CAS)分区:
出版当年[2017]版:
大类 | 4 区 医学
小类 | 4 区 肿瘤学 4 区 病理学
最新[2023]版:
第一作者:
第一作者机构: [1]Huazhong Univ Sci & Technol, Tongji Med Coll, Union Hosp, Canc Ctr, 156 Wujiadun, Wuhan 430023, Hubei, Peoples R China; [2]Sun Yat Sen Univ, Canc Ctr, 2State Key Lab Oncol South China, Collaborat Innovat Ctr Canc Med, Guangzhou, Guangdong, Peoples R China; [3]Sun Yat Sen Univ, Canc Ctr, Dept Mol Diagnost, Guangzhou, Guangdong, Peoples R China
通讯作者:
通讯机构: [1]Huazhong Univ Sci & Technol, Tongji Med Coll, Union Hosp, Canc Ctr, 156 Wujiadun, Wuhan 430023, Hubei, Peoples R China;
推荐引用方式(GB/T 7714):
APA:
MLA:

资源点击量:46425 今日访问量:0 总访问量:3323 更新日期:2024-11-01 建议使用谷歌、火狐浏览器 常见问题

版权所有©2020 四川省肿瘤医院 技术支持:重庆聚合科技有限公司 地址:成都市人民南路四段55号